Lactococcus lactis-based vaccines Current status and future perspectives

被引：20
作者：
Bahey-El-Din, Mohammed [1 ,2 ,3 ,4 ]
Gahan, Cormac G. M. [1 ,2 ,3 ]
机构：
[1] Univ Coll Cork, Dept Microbiol, Cork, Ireland
[2] Univ Coll Cork, Sch Pharm, Cork, Ireland
[3] Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
[4] Univ Alexandria, Fac Pharm, Dept Pharmaceut Microbiol, Alexandria, Egypt
来源：
HUMAN VACCINES | 2011年 / 7卷 / 01期
关键词：
Lactococcus lactis; vaccine delivery; GEM; biological containment; COMPLETE GENOME SEQUENCE; MUCOSAL DELIVERY; MURINE INTERLEUKIN-2; ORAL IMMUNIZATION; ESCHERICHIA-COLI; PROTECTION; ANTIGEN; IMMUNOGENICITY; RESPONSES; TETANUS;
D O I：
10.4161/hv.7.1.13631
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Lactococcus lactis offers significant potential as a platform for the delivery of vaccines especially via mucosal routes of administration. The organism has an established history of safe use in the food industry and is highly amenable to genetic manipulation, with many systems available for efficient production of secreted and surface-expressed proteins. Here we describe the benefits of using this organism as a vaccine delivery platform and outline how L. lactis based antigen delivery may be improved. Finally we discuss the safe use of L. lactis vectors and outline the potential for use of biological containment systems and killed lactococcal preparations.
引用
收藏
页码：106 / 109
页数：4
相关论文
共 36 条
[11]   Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV [J].
Daniel, Catherine ;
Sebbane, Florent ;
Poiret, Sabine ;
Goudercourt, Denise ;
Dewulf, Joelle ;
Mullet, Chantal ;
Simonet, Michel ;
Pot, Bruno .
VACCINE, 2009, 27 (08) :1141-1144
[12]   Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection [J].
Hanniffy, Sean B. ;
Carter, Andrew T. ;
Hitchin, Ed ;
Wells, Jerry M. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (02) :185-193
[13]   New vaccines for tuberculosis [J].
Kaufmann, Stefan H. E. ;
Hussey, Gregory ;
Lambert, Paul-Henri .
LANCET, 2010, 375 (9731) :2110-2119
[14]   Lactococcus lactis as host for overproduction of functional membrane proteins [J].
Kunji, ERS ;
Slotboom, DJ ;
Poolman, B .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2003, 1610 (01) :97-108
[15]   Plasmids of lactococci - genetic accessories or genetic necessities? [J].
Mills, S ;
McAuliffe, OE ;
Coffey, A ;
Fitzgerald, GF ;
Ross, RP .
FEMS MICROBIOLOGY REVIEWS, 2006, 30 (02) :243-273
[16]   Mucosal vaccines: the promise and the challenge [J].
Neutra, MR ;
Kozlowski, PA .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (02) :148-158
[17]  
Nouaille Sebastien, 2003, Genet Mol Res, V2, P102
[18]   Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination [J].
Pei, HD ;
Liu, JF ;
Cheng, Y ;
Sun, CM ;
Wang, C ;
Lu, YP ;
Ding, J ;
Zhou, J ;
Xiang, H .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2005, 68 (02) :220-227
[19]   Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations [J].
Ramasamy, R. ;
Yasawardena, S. ;
Zomer, A. ;
Venema, G. ;
Kok, J. ;
Leenhouts, K. .
VACCINE, 2006, 24 (18) :3900-3908
[20]   Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C [J].
Robinson, K ;
Chamberlain, LM ;
Lopez, MC ;
Rush, CM ;
Marcotte, H ;
Le Page, RWF ;
Wells, JM .
INFECTION AND IMMUNITY, 2004, 72 (05) :2753-2761
1234